(EMN) Eastman Chemical - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 8.185m USD | Total Return: -9.4% in 12m
Specialty Polymers, Plasticizers, Acetate Fibers, Chemical Intermediates
Total Rating 40
Safety 79
Buy Signal 0.19
Specialty Chemicals
Industry Rotation: +0.5
Industry Rotation: +0.5
Market Cap:
8.19B
Avg Turnover: 75.2M
Avg Turnover: 75.2M
Risk 3d forecast
Volatility31.3%
VaR 5th Pctl5.00%
VaR vs Median-2.89%
Reward TTM
Sharpe Ratio-0.19
Rel. Str. IBD36.7
Rel. Str. Peer Group31.7
Character TTM
Beta0.914
Beta Downside1.205
Hurst Exponent0.450
Drawdowns 3y
Max DD48.40%
CAGR/Max DD-0.02
CAGR/Mean DD-0.07
EPS (Earnings per Share)
EPS CAGR: -22.46%
EPS Trend: -43.0%
EPS Trend: -43.0%
Last SUE: 0.22
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -6.26%
Rev. Trend: -75.5%
Rev. Trend: -75.5%
Last SUE: -0.03
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Confidence
Description: EMN Eastman Chemical
Eastman Chemical Company is a global specialty materials firm headquartered in Kingsport, Tennessee. The company operates through four primary segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers. Its portfolio includes amine derivatives, copolyesters, cellulosic biopolymers, and acetate tow, serving diverse end-markets such as transportation, medical, agriculture, and building and construction.
The specialty chemicals sector is characterized by high barriers to entry due to complex manufacturing processes and significant research and development requirements. Eastman utilizes a vertically integrated business model, converting basic chemical building blocks into high-margin, functional materials tailored for specific industrial applications. This integration allows for greater cost control over raw materials like olefins and acetyls.
Investors can further evaluate the companys financial health and valuation metrics on ValueRay. Founded in 1920, Eastman Chemical has transitioned from a traditional commodity chemical producer to a provider of value-added specialty products, reducing its exposure to cyclical price fluctuations in the broader energy and basic materials markets.
- Circular economy investments and molecular recycling scale-up drive long-term margin expansion
- Volatile raw material costs for olefins and acetyls impact quarterly earnings
- Global automotive and construction demand fluctuations dictate specialty plastics revenue growth
- Cellulose acetate pricing and cigarette tow volume stability support consistent cash flow
- Strategic portfolio shifts toward high-margin specialty materials reduce commodity price exposure
Piotroski VR‑10 (Strict)
5.0
| Net Income: 399.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 14.91% < 20% (prev 17.43%; Δ -2.52% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.00b > Net Income 399.0m |
| Net Debt (4.66b) to EBITDA (1.19b): 3.92 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.9m) vs 12m ago -2.54% < -2% |
| Gross Margin: 19.77% > 18% (prev 0.25%; Δ 1.95k% > 0.5%) |
| Asset Turnover: 57.23% > 50% (prev 62.53%; Δ -5.31% > 0%) |
| Interest Coverage Ratio: 3.15 > 6 (EBITDA TTM 1.19b / Interest Expense TTM 213.0m) |
Altman Z''
4.17
| A: 0.08 (Total Current Assets 4.06b - Total Current Liabilities 2.77b) / Total Assets 15.22b |
| B: 0.66 (Retained Earnings 10.11b / Total Assets 15.22b) |
| C: 0.04 (EBIT TTM 672.0m / Avg Total Assets 15.10b) |
| D: 1.09 (Book Value of Equity 9.97b / Total Liabilities 9.14b) |
| Altman-Z'' Score: 4.17 = AA |
Beneish M
-2.86
| DSRI: 1.05 (Receivables 1.22b/1.26b, Revenue 8.64b/9.36b) |
| GMI: 1.26 (GM 19.77% / 24.83%) |
| AQI: 0.99 (AQ_t 0.36 / AQ_t-1 0.36) |
| SGI: 0.92 (Revenue 8.64b / 9.36b) |
| TATA: -0.04 (NI 399.0m - CFO 1.00b) / TA 15.22b) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of EMN shares?
As of May 19, 2026, the stock is trading at USD 70.94 with a total of 562,660 shares traded.
Over the past week, the price has changed by -4.96%, over one month by -3.67%, over three months by -10.55% and over the past year by -9.41%.
Over the past week, the price has changed by -4.96%, over one month by -3.67%, over three months by -10.55% and over the past year by -9.41%.
Is EMN a buy, sell or hold?
Eastman Chemical has received a consensus analysts rating of 4.15.
Therefore, it is recommended to buy EMN.
- StrongBuy: 10
- Buy: 3
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EMN price?
| Analysts Target Price | 84.3 | 18.9% |
Eastman Chemical (EMN) - Fundamental Data Overview
as of 18 May 2026
P/E Trailing = 20.6879 P/E Forward = 11.4286
P/S = 0.9475
P/B = 1.4015
P/EG = 0.6279
Revenue TTM = 8.64b USD
EBIT TTM = 672.0m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 4.45b USD (from longTermDebt, last quarter)
Short Term Debt = 770.0m USD (from shortTermDebt, last quarter)
Debt = 5.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.66b USD (from netDebt column, last quarter)
Enterprise Value = 12.85b USD (8.19b + Debt 5.33b - CCE 665.0m)
Interest Coverage Ratio = 3.15 (Ebit TTM 672.0m / Interest Expense TTM 213.0m)
EV/FCF = 25.79x (Enterprise Value 12.85b / FCF TTM 498.0m)
FCF Yield = 3.88% (FCF TTM 498.0m / Enterprise Value 12.85b)
FCF Margin = 5.76% (FCF TTM 498.0m / Revenue TTM 8.64b)
Net Margin = 4.62% (Net Income TTM 399.0m / Revenue TTM 8.64b)
Gross Margin = 19.77% ((Revenue TTM 8.64b - Cost of Revenue TTM 6.93b) / Revenue TTM)
Gross Margin QoQ = 19.80% (prev 17.13%)
Tobins Q-Ratio = 0.84 (Enterprise Value 12.85b / Total Assets 15.22b)
Interest Expense / Debt = 0.92% (Interest Expense 49.0m / Debt 5.33b)
Taxrate = 21.32% (29.0m / 136.0m)
NOPAT = 528.7m (EBIT 672.0m * (1 - 21.32%))
Current Ratio = 1.47 (Total Current Assets 4.06b / Total Current Liabilities 2.77b)
Debt / Equity = 0.89 (Debt 5.33b / totalStockholderEquity, last quarter 6.01b)
Debt / EBITDA = 3.92 (Net Debt 4.66b / EBITDA 1.19b)
Debt / FCF = 9.36 (Net Debt 4.66b / FCF TTM 498.0m)
Total Stockholder Equity = 5.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.64% (Net Income 399.0m / Total Assets 15.22b)
RoE = 6.77% (Net Income TTM 399.0m / Total Stockholder Equity 5.89b)
RoCE = 6.50% (EBIT 672.0m / Capital Employed (Equity 5.89b + L.T.Debt 4.45b))
RoIC = 4.83% (NOPAT 528.7m / Invested Capital 10.95b)
WACC = 5.86% (E(8.19b)/V(13.51b) * Re(9.20%) + D(5.33b)/V(13.51b) * Rd(0.92%) * (1-Tc(0.21)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.11 | Cagr: -1.44%
[DCF] Terminal Value 87.32% ; FCFF base≈528.8m ; Y1≈587.1m ; Y5≈767.9m
[DCF] Fair Price = 156.6 (EV 22.56b - Net Debt 4.66b = Equity 17.90b / Shares 114.3m; r=6.0% [WACC]; 5y FCF grow 12.71% → 3.0% )
EPS Correlation: -43.05 | EPS CAGR: -22.46% | SUE: 0.22 | # QB: 0
Revenue Correlation: -75.54 | Revenue CAGR: -6.26% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.81 | Chg30d=+4.33% | Revisions=+38% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.97 | Chg30d=+11.04% | Revisions=+69% | Analysts=13
EPS current Year (2026-12-31): EPS=6.37 | Chg30d=+6.29% | Revisions=+73% | GrowthEPS=+17.5% | GrowthRev=+4.8%
EPS next Year (2027-12-31): EPS=7.01 | Chg30d=+2.86% | Revisions=+47% | GrowthEPS=+10.1% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: +73%